|
Characteristic
|
Placebo, n = 410 (%)
|
GV-971, n = 408 (%)
|
p value
|
|---|
|
Age—years
|
69.7 ± 8.20
|
69.6 ± 8.12
|
0.7374 [b]
|
|
≤ 65 years
|
131 (32.0%)
|
132 (32.4%)
|
0.9021 [c]
|
|
> 65 years
|
279 (68.0%)
|
276 (67.6%)
| |
|
Sex
| | |
0.8242 [c]
|
|
Male—no. (%)
|
177 (43.2%)
|
173 (42.4%)
| |
|
Female—no. (%)
|
233 (56.8%)
|
235 (57.6%)
| |
|
Han ethnicity—no. (%)
|
402 (98.0%)
|
398 (97.5%)
|
0.6261 [c]
|
|
Education—years
| | |
0.7394 [c]
|
|
> 6 years
|
335 (81.7%)
|
337 (82.6%)
| |
|
≤ 6 years
|
75 (18.3%)
|
71 (17.4%)
| |
|
APOE ε4 carrier—no. (%)
|
199 (48.5%)
|
214 (52.5%)
|
0.2758 [c]
|
|
MMSE score
|
19.5 ± 4.5
|
19.4 ± 4.4
|
0.5795 [b]
|
|
MMSE < 11
|
1 (0.2%)
|
0
|
0.6815 [d]
|
|
11 ≤ MMSE < 15
|
72 (17.6%)
|
68 (16.7%)
| |
|
15 ≤ MMSE ≤ 19
|
118 (28.8%)
|
122 (29.9%)
| |
|
20 ≤ MMSE ≤ 26
|
219 (53.4%)
|
216 (52.9%)
| |
|
26 < MMSE
|
0
|
2 (0.5%)
| |
|
Duration since symptom onset (months)
|
31.46 ± 20.79
|
30.42 ± 20.59
|
0.6087 [b]
|
|
ADAS-Cog12
|
20.88 ± 10.00
|
21.28 ± 10.14
|
0.5638 [b]
|
|
ADCS-ADL
|
64.2 ± 10.1
|
64.0 ± 11.2
|
0.8910 [b]
|
|
NPI
|
5.9 ± 8.6
|
5.6 ± 8.0
|
0.5651 [b]
|
- [a] refers to the t test; [b] refers to the Wilcoxon rank sum test; [c] refers to the chi-square test; [d] refers to Fisher’s exact test
